| Pten in stromal fibroblasts suppresses mammary epithelial tumours AJ Trimboli, CZ Cantemir-Stone, F Li, JA Wallace, A Merchant, N Creasap, ... Nature 461 (7267), 1084-1091, 2009 | 605 | 2009 |
| Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates RP Lyon, JR Setter, TD Bovee, SO Doronina, JH Hunter, ME Anderson, ... Nature biotechnology 32 (10), 1059, 2014 | 452 | 2014 |
| Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320 A Bronisz, J Godlewski, JA Wallace, AS Merchant, MO Nowicki, ... Nature Cell Biology 14 (2), 159-167, 2011 | 328 | 2011 |
| Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models F Li, KK Emmerton, M Jonas, X Zhang, JB Miyamoto, JR Setter, ... Cancer research 76 (9), 2710-2719, 2016 | 247 | 2016 |
| Trisomy represses ApcMin-mediated tumours in mouse models of Down’s syndrome TE Sussan, A Yang, F Li, MC Ostrowski, RH Reeves Nature 451 (7174), 73-75, 2008 | 187 | 2008 |
| Characterization of SGN-CD123A, a potent CD123-directed antibody–drug conjugate for acute myeloid leukemia F Li, MK Sutherland, C Yu, RB Walter, L Westendorf, J Valliere-Douglass, ... Molecular cancer therapeutics 17 (2), 554-564, 2018 | 93 | 2018 |
| TRIP6 is a RIP2-associated common signaling component of multiple NF-κB activation pathways L Li, LH Bin, F Li, Y Liu, D Chen, Z Zhai, HB Shu Journal of cell science 118 (3), 555, 2005 | 72 | 2005 |
| Tumor-associated macrophages can contribute to antitumor activity through FcγR-mediated processing of antibody–drug conjugates F Li, M Ulrich, M Jonas, IJ Stone, G Linares, X Zhang, L Westendorf, ... Molecular cancer therapeutics 16 (7), 1347-1354, 2017 | 59 | 2017 |
| Transformed epithelial cells and fibroblasts/myofibroblasts interaction in breast tumor: A mathematical model and experiments Y Kim, J Wallace, F Li, M Ostrowski, A Friedman Journal of mathematical biology 61 (3), 401-421, 2010 | 54 | 2010 |
| Identification of a novel serine/threonine kinase that inhibits TNF-induced NF-[kappa] B activation and p53-induced transcription J Huang, L Teng, T Liu, L Li, D Chen, F Li, LG Xu, Z Zhai, HB Shu Biochemical and biophysical research communications 309 (4), 774-778, 2003 | 53 | 2003 |
| Pten in the breast tumor microenvironment: modeling tumor–stroma coevolution JA Wallace, F Li, G Leone, MC Ostrowski Cancer research 71 (4), 1203-1207, 2011 | 51 | 2011 |
| Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer JA Wallace, F Li, S Balakrishnan, CZ Cantemir-Stone, T Pecot, C Martin, ... PloS one 8 (8), 2013 | 48 | 2013 |
| Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction F Li, ML Ulrich, VFS Shih, JH Cochran, JH Hunter, L Westendorf, J Neale, ... Molecular cancer therapeutics 18 (4), 780-787, 2019 | 46 | 2019 |
| Targeted delivery of cytotoxic NAMPT inhibitors using antibody–drug conjugates CS Neumann, KC Olivas, ME Anderson, JH Cochran, S Jin, F Li, ... Molecular cancer therapeutics 17 (12), 2633-2642, 2018 | 38 | 2018 |
| Analysis of the IKKβ/NF‐κB signaling pathway during embryonic angiogenesis Y Hou, F Li, M Karin, MC Ostrowski Developmental Dynamics 237 (10), 2926-2935, 2008 | 25 | 2008 |
| Relationship between in vivo antitumor activity of ADC and payload release in preclinical models F Li, X Zhang, K Emmerton, M Jonas, J Setter, B Arthur, N Okeley, R Lyon, ... Cancer Research 74 (19 Supplement), 3694-3694, 2014 | 13 | 2014 |
| Characterization and circumvention of drug resistance mechanisms in SGN-35-resistant HL and ALCL clonal cell lines TS Lewis, K Gordon, F Li, A Weimann, R Bruders, J Miyamoto, D Chace, ... Cancer Research 74 (19 Supplement), 688-688, 2014 | 11 | 2014 |
| Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer D Toader, SP Fessler, SD Collins, PR Conlon, R Bollu, KC Catcott, ... Molecular Cancer Therapeutics, MCT-22-0786, 2023 | 6 | 2023 |
| ETS transcription factors in the tumor microenvironment F Li, JA Wallace, MC Ostrowski The Open Cancer Journal 3 (1), 2010 | 3 | 2010 |
| Combination therapy using a liv1-adc and a chemotherapeutic D Sussman, F Li, A Kostic US Patent App. 16/085,511, 2019 | 2 | 2019 |
Mike OstrowskiHollings Cancer Center, Medical University of South Carolina在 musc.edu 的電子郵件地址已通過驗證
